Healthcare >> Analyst Interviews >> February 14, 2005


DAVID RISINGER joined Merrill Lynch in July 1999 as a First Vice President responsible for coverage of the Healthcare Information Technology and Distribution sector. In November 2002, he assumed coverage of US major pharmaceuticals. Mr. Risinger covers the US pharmaceutical industry for Merrill Lynch's Equity Research Department in the United States. In 2004, he was ranked a 'Runner Up' in the US Major Pharmaceutical category of the Institutional Investor poll. Prior to joining Merrill Lynch as a First Vice President, he spent eight years in pharmaceutical and healthcare equity research at Morgan Stanley and Dillon Read. Mr. Risinger was a top-ranked healthcare distribution and IT analyst in the Institutional Investor poll in 2000, 2001 and 2002. In 1998 and 1999, he was ranked in the Reuters Survey for his research in the healthcare industry. Mr. Risinger graduated from Bucknell University in 1991 with a BA in Political Science and received his CFA Charter in 1995. Profile
TWST: As you look at the pharma space today, what are the top issues

from your perspective?

Mr. Risinger: The number one issue is litigation. There are a number of

binary events that are